BridgeMD
New treatment option for Prostate Cancer
Official title Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
ClinicalTrials.gov ID: NCT07011342
What this study is testing
What is 18F-rhPSMA-7.3?
18F-rhPSMA-7.3 is an investigational medicine, being studied as a potential treatment for prostate cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Adult males 18 years or older;
- Patient must have a pre-treatment MRI;
- Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months...
- Intermediate risk disease as defined by American Urology Academy (AUA)/National Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)
- Life Expectancy of 10 years or more;
You likely can't join if
- Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a...
- Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.
See the full eligibility criteria
- Adult males 18 years or older;
- Patient must have a pre-treatment MRI;
- Patient underwent SOC focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment;
- Intermediate risk disease as defined by American Urology Academy (AUA)/National Comprehensive Cancer Network (NCCN) guidelines (see Appendix A)
- Life Expectancy of 10 years or more;
- Underwent standard template biopsy before treatment with a minimum of 2 cores into the MRI visible lesion if lesion was present;
- Patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed...
- Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points.
- Patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at...
- Patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Hackensack, New Jersey, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hackensack, New Jersey, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.